Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 29, 2020 08:05 ET | Source: Affimed N.V.

Affimed Highlights Study Design of its AFM13 REDIRECT Trial at the ASCO 2020 Virtual Meeting

REDIRECT is a Registration-directed Phase II Open-label Multicenter Study to Assess the Efficacy and Safety of AFM13 in Patients with Relapsed or Refractory CD30 positive Peripheral T-cell Lymphoma...
May 28, 2020 05:00 ET | Source: Affimed N.V.

Affimed to Present at the Jefferies Virtual Healthcare Conference

Heidelberg, Germany, May 28, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced...
May 15, 2020 05:00 ET | Source: Affimed N.V.

Affimed Announces Abstracts on Innate Cell Engagers from its ROCK® Platform Accepted for Presentation at AACR Virtual Annual Meeting II

Affimed researchers served as co-authors on an abstract for RO7297089 with scientific collaborators from Genentech, a member of the Roche GroupAffimed will host a live teleconference at 8am Eastern...
April 28, 2020 06:35 ET | Source: Affimed N.V.

Affimed Reports 2019 Financial Results and Recent Operational Progress

AFM24: First patient dosed in first-in-human clinical study for advanced EGFR-expressing solid tumors, including colon, lung and other cancersAFM13: Initiated registration-directed study in...
April 16, 2020 07:30 ET | Source: Affimed N.V.

Affimed Announces First Patient Successfully Dosed in First-in-Human Phase 1/2A Study of AFM24 for the Treatment of Advanced EGFR-Expressing Solid Tumors Including Colon, Lung and Other Cancers

AFM24, designed to activate innate immunity to broadly target EGFR-expressing solid tumors regardless of mutational status, has the potential to improve efficacy and safety over currently available...
April 02, 2020 06:30 ET | Source: Affimed N.V.

Affimed Provides COVID-19-Related Business Update and Announces Full Year 2019 Financial Results Conference Call on April 28, 2020

Heidelberg, Germany, April 2, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today provided an...
April 01, 2020 16:01 ET | Source: Affimed N.V.

Affimed Announces FDA Granted Orphan Drug Designation for Lead Innate Cell Engager AFM13 for the Treatment of T-cell Lymphoma

Heidelberg, Germany, April 1, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that...
March 26, 2020 07:30 ET | Source: Affimed N.V.

Affimed Announces Participation at Upcoming Virtual Investor Conferences

Heidelberg, Germany, March 26, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that...
March 17, 2020 07:30 ET | Source: Affimed N.V.

Affimed Announces Appointment of Arndt Schottelius, M.D. Ph.D. as Chief Scientific Officer

Dr. Schottelius, former executive at Kymab, MorphoSys and Genentech, brings extensive innate immunity expertise and successful record of advancing discovery research into preclinical and clinical...
February 19, 2020 07:30 ET | Source: Affimed N.V.

Affimed to Present at the SVB Leerink 9th Annual Global Healthcare Conference

Heidelberg, Germany, February 19, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced...